Back to top
more

Charles River Laboratories International (CRL)

(Delayed Data from NYSE)

$180.96 USD

180.96
830,357

+2.38 (1.33%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $180.89 -0.07 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pediatrix Medical Group (MD) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Pediatrix Medical Group (MD) delivered earnings and revenue surprises of 18.92% and 2.21%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Charles River (CRL) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

CRL Gears Up for Q3 Earnings: Here's What You Need to Know

by Zacks Equity Research

Growth across all businesses within the Manufacturing segment is likely to have contributed to Charles River's Q3 revenues, offset by lower biopharmaceutical demand.

CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch

by Zacks Equity Research

Charles River launches Retrogenix Non-Human Protein Library to provide early insights into how therapeutics interact with non-human protein targets in vitro.

CRL to Aid Lundbeck's Neurological Drug Research With AI-Backed Logica

by Zacks Equity Research

Charles River and Lundbeck sign an agreement to use Logica to advance the discovery of novel neurological drugs.

CRL Stock to Gain From Strategic Neuroscience Partnership With CEBINA

by Zacks Equity Research

Charles River collaborates with CEBINA as part of the DanubeNeuro program to advance innovation in neurodegeneration.

CRL Stock May Benefit From New Neuroscience Research Collaboration

by Zacks Equity Research

Charles River's new alliance with Insightec to advance therapeutic development using focused ultrasound in neuroscience.

Why Is Charles River (CRL) Down 5.3% Since Last Earnings Report?

by Zacks Equity Research

Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Charles River (CRL) International Revenue Trends Deserve Your Attention

by Zacks Equity Research

Examine Charles River's (CRL) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Charles River (CRL) Q2 Earnings Beat Estimates, 2024 View Down

by Zacks Equity Research

Charles River's (CRL) Manufacturing business segments report organic revenue growth, partially offset by lower revenues in the DSA and RMS segments.

Here's What Key Metrics Tell Us About Charles River (CRL) Q2 Earnings

by Zacks Equity Research

While the top- and bottom-line numbers for Charles River (CRL) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Charles River Laboratories (CRL) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Charles River (CRL) delivered earnings and revenue surprises of 17.15% and 0.09%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Unlocking Q2 Potential of Charles River (CRL): Exploring Wall Street Estimates for Key Metrics

by Zacks Equity Research

Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Here's How Charles River (CRL) is Placed Ahead of Q2 Earnings

by Zacks Equity Research

Growth across Microbial Solutions and Biologics Testing and CDMO businesses is likely to have contributed to Charles River's (CRL) Q2 revenues, offset by lower biopharmaceutical demand.

Charles River (CRL) Teams Up to Aid Stargardt's Disease Therapy

by Zacks Equity Research

Charles River (CRL) signs an agreement with AAVantgarde to produce GMP plasmid DNA for Stargardt's disease program.

Charles River (CRL) Could be an Apt Pick Right Now: Here's Why

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) due to its business performance and strategic buyouts.

Charles River's (CRL) RMS Growth Aids Amid FX Headwind

by Zacks Equity Research

Charles River (CRL) broadens the scope of its products and services across the drug discovery and early-stage development continuum through focused acquisitions.

Charles River (CRL) Inks CDMO Deal With Gates Institutes

by Zacks Equity Research

Charles River (CRL) signs a lentiviral vector contract development and manufacturing organization agreement with Gates Institute to help develop chimeric antigen receptor (CAR) T-cell therapies.

Charles River (CRL) Advances in T-Cell Therapy With New Alliance

by Zacks Equity Research

Charles River (CRL) and Captain T Cell announced an agreement on plasmid DNA and retrovirus vector production program for the treatment of patients having solid tumor.

Charles River (CRL) Partners to Reduce Animal Research Usage

by Zacks Equity Research

Charles River (CRL) announces the development of non-clinical VCG with Sanofi to reduce the use of animals in research.

Charles River (CRL) Launches Viral Vector Tech Transfer Program

by Zacks Equity Research

Charles River's (CRL) new Fast Track and Modular frameworks facilitate product development continuity via accelerated process transfer to its viral vector Center of Excellence.

Reasons to Hold Charles River (CRL) in Your Portfolio Now

by Zacks Equity Research

Investors remain optimistic about Charles River (CRL), owing to its acquisitions, thriving DSA segment and financial stability.

Charles River (CRL) Banks on RMS Growth Amid Competition

by Zacks Equity Research

Charles River's (CRL) RMS arm sees lesser impact on demand than other life science sectors despite macroeconomic challenges in China.

Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for JSMD